Does the type of surgical operation influence the changes observed in fibrinolytic activity after cardiopulmonary bypass?
Sánchez
J M
JM
Martin
J M
JM
D000991:Antithrombins / Q000032:analysis / Q000502:physiology; D001021:Aortic Valve / Q000601:surgery; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D016022:Case-Control Studies; D001026:Coronary Artery Bypass; D017558:Elective Surgical Procedures; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis / Q000502:physiology; D005340:Fibrinogen / Q000032:analysis / Q000502:physiology; D005342:Fibrinolysis / Q000502:physiology*; D006350:Heart Valve Prosthesis; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D008943:Mitral Valve / Q000601:surgery; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000502:physiology; D010960:Plasminogen Activators / Q000097:blood / Q000502:physiology; D011446:Prospective Studies; D015842:Serine Proteinase Inhibitors / Q000097:blood / Q000502:physiology; D013924:Thrombophlebitis / Q000209:etiology; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000502:physiology
D000991:Antithrombins; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D005340:Fibrinogen; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator